"Novo Holdings' $7 Billion Annual Investment Ambitions Fueled by Ozempic and Wegovy Success"
Novo Holdings' investment ambitions are bolstered by the success of diabetes drugs Ozempic and Wegovy, which have generated significant income. This success is expected to fuel the company's investment activities in various sectors.